- Category
- Defining Matters
- Date
- Dec. 16, 2020
- Title
-
Kramer Levin Advises Pontifax in $50 million Convertible Note Purchase and Security Agreement for Opiant Pharmaceuticals
On Dec. 10, 2020, leading Israeli life science fund, Pontifax, announced that it has entered into a $50 million convertible Note Purchase and Security Agreement with Opiant Pharmaceuticals Inc., a specialty pharmaceutical company, that will allow Opiant to draw up to $50 million in three tranches.
Related People
-
-
Harry Rubin
-
- Partner
- Chair, Technology and IP Transactions
- New York
- vcard
-
-
-
John Bessonette
-
- Partner
- New York
- vcard
-
-
-
Barry Herzog
-
- Partner
- Chair, Tax
- New York
- vcard
-
-
-
Mariya Khvatskaya
-
- Associate
- New York
- vcard
-
